{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:15:46Z","timestamp":1779095746735,"version":"3.51.4"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11864-026-01383-3","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:45:20Z","timestamp":1779086720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Therapy for Solitary Fibrous Tumor"],"prefix":"10.1007","volume":"27","author":[{"given":"Georgios M.","family":"Stergiopoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Tinoco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven I.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"4","key":"1383_CR1","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/cncr.10328","volume":"94","author":"JS Gold","year":"2002","unstructured":"Gold JS, Antonescu CR, Hajdu C, et al. Clinicopathologic correlates of solitary fibrous tumors. Cancer. 2002;94(4):1057\u201368.","journal-title":"Cancer"},{"key":"1383_CR2","volume-title":"Classification of Tumours Editorial Board","author":"EG Demicco","year":"2020","unstructured":"Demicco EG, Fritchie KJ, Han A. Solitary Fibrous Tumour.Classification of Tumours Editorial Board. IARC; 2020."},{"issue":"2","key":"1383_CR3","doi-asserted-by":"publisher","first-page":"e0246958","DOI":"10.1371\/journal.pone.0246958","volume":"16","author":"G de Pinieux","year":"2021","unstructured":"de Pinieux G, Karanian M, Le Loarer F, et al. Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE. 2021;16(2):e0246958.","journal-title":"PLoS ONE"},{"issue":"1","key":"1383_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajim.4700220103","volume":"22","author":"P Klemperer","year":"1992","unstructured":"Klemperer P, Coleman BR. Primary neoplasms of the pleura. A report of five cases. Am J Ind Med. 1992;22(1):1\u201331.","journal-title":"Am J Ind Med"},{"issue":"5","key":"1383_CR5","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1245\/s10434-014-4130-7","volume":"22","author":"A Gronchi","year":"2015","unstructured":"Gronchi A, Miceli R, Allard MA, et al. Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection. Ann Surg Oncol. 2015;22(5):1447\u201354.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"1383_CR6","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1097\/00000478-199812000-00007","volume":"22","author":"AV Vallat-Decouvelaere","year":"1998","unstructured":"Vallat-Decouvelaere AV, Dry SM, Fletcher CD. Atypical and malignant solitary fibrous tumors in extrathoracic locations: evidence of their comparability to intra-thoracic tumors. Am J Surg Pathol. 1998;22(12):1501\u201311.","journal-title":"Am J Surg Pathol"},{"issue":"9","key":"1383_CR7","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.ejso.2009.02.015","volume":"35","author":"IM Cranshaw","year":"2009","unstructured":"Cranshaw IM, Gikas PD, Fisher C, Thway K, Thomas JM, Hayes AJ. Clinical outcomes of extra-thoracic solitary fibrous tumours. Eur J Surg Oncol. 2009;35(9):994\u20138.","journal-title":"Eur J Surg Oncol"},{"key":"1383_CR8","doi-asserted-by":"crossref","unstructured":"Lottin M, Escande A, Bauchet L et al. Intracranial solitary fibrous tumour management: A French multicentre retrospective study. Cancers Basel. 2023;15(3).","DOI":"10.3390\/cancers15030704"},{"issue":"4","key":"1383_CR9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/cancers14041064","volume":"14","author":"A de Bernardi","year":"2022","unstructured":"de Bernardi A, Dufresne A, Mishellany F, Blay JY, Ray-Coquard I, Brahmi M. Novel therapeutic options for solitary fibrous tumor: Antiangiogenic therapy and beyond. Cancers Basel. 2022;14(4):1064.","journal-title":"Cancers Basel"},{"issue":"8","key":"1383_CR10","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1093\/annonc\/mdx250","volume":"28","author":"S Salas","year":"2017","unstructured":"Salas S, Resseguier N, Blay JY, et al. Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol. 2017;28(8):1979\u201387.","journal-title":"Ann Oncol"},{"issue":"7","key":"1383_CR11","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1245\/s10434-020-09306-8","volume":"28","author":"H Outani","year":"2021","unstructured":"Outani H, Kobayashi E, Wasa J, et al. Clinical outcomes of patients with metastatic solitary fibrous tumors: A Japanese musculoskeletal oncology group (JMOG) multiinstitutional study. Ann Surg Oncol. 2021;28(7):3893\u2013901.","journal-title":"Ann Surg Oncol"},{"key":"1383_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.anndiagpath.2018.01.004","volume":"34","author":"A Ronchi","year":"2018","unstructured":"Ronchi A, Cozzolino I, Zito Marino F, et al. Extrapleural solitary fibrous tumor: a distinct entity from pleural solitary fibrous tumor. An update on clinical, molecular and diagnostic features. Ann Diagn Pathol. 2018;34:142\u201350.","journal-title":"Ann Diagn Pathol"},{"issue":"13","key":"1383_CR13","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1245\/s10434-017-6092-z","volume":"24","author":"S Gholami","year":"2017","unstructured":"Gholami S, Cassidy MR, Kirane A, et al. Size and location are the most important risk factors for malignant behavior in resected solitary fibrous tumors. Ann Surg Oncol. 2017;24(13):3865\u201371.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"1383_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1007\/s00701-024-06191-y","volume":"166","author":"C Champeaux Depond","year":"2024","unstructured":"Champeaux Depond C, Zouaoui S, Darlix A, et al. Descriptive epidemiology of 399 histologically confirmed newly diagnosed meningeal solitary fibrous tumours and haemangiopericytomas in France: 2006-2015. Acta Neurochir Wien. 2024;166(1):320.","journal-title":"Acta Neurochir Wien"},{"key":"1383_CR15","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1016\/j.wneu.2022.10.092","volume":"169","author":"ME El-Abtah","year":"2023","unstructured":"El-Abtah ME, Murayi R, Ejikeme T, et al. A single-center retrospective analysis of intracranial and spinal solitary fibrous tumor\/hemangiopericytoma clinical outcomes: Sex association with aggressiveness. World Neurosurg. 2023;169:e190\u20136.","journal-title":"World Neurosurg"},{"issue":"5","key":"1383_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00401-013-1117-6","volume":"125","author":"L Schweizer","year":"2013","unstructured":"Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013;125(5):651\u20138.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"1383_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/ng.2509","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45(2):180\u20135.","journal-title":"Nat Genet"},{"issue":"2","key":"1383_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/ng.2522","volume":"45","author":"J Chmielecki","year":"2013","unstructured":"Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45(2):131\u20132.","journal-title":"Nat Genet"},{"issue":"10","key":"1383_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/gcc.22083","volume":"52","author":"A Mohajeri","year":"2013","unstructured":"Mohajeri A, Tayebwa J, Collin A, et al. Comprehensive genetic analysis identifies a pathognomonic NAB2\/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer. 2013;52(10):873\u201386.","journal-title":"Genes Chromosomes Cancer"},{"issue":"7","key":"1383_CR20","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.humpath.2015.03.014","volume":"46","author":"EG Demicco","year":"2015","unstructured":"Demicco EG, Wani K, Fox PS, et al. Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. Hum Pathol. 2015;46(7):1015\u201326.","journal-title":"Hum Pathol"},{"issue":"5","key":"1383_CR21","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1158\/1535-7163.MCT-09-1205","volume":"9","author":"S Stacchiotti","year":"2010","unstructured":"Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010;9(5):1286\u201397.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1383_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/path.2715","volume":"221","author":"M Hajdu","year":"2010","unstructured":"Hajdu M, Singer S, Maki RG, Schwartz GK, Keohan ML, Antonescu CR. IGF2 over-expression in solitary fibrous tumours is independent of anatomical location and is related to loss of imprinting. J Pathol. 2010;221(3):300\u20137.","journal-title":"J Pathol"},{"issue":"1","key":"1383_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.canlet.2013.12.001","volume":"346","author":"RC Ji","year":"2014","unstructured":"Ji RC. Hypoxia and lymphangiogenesis in tumor microenvironment and metastasis. Cancer Lett. 2014;346(1):6\u201316.","journal-title":"Cancer Lett"},{"issue":"3","key":"1383_CR24","first-page":"763","volume":"148","author":"E Hatva","year":"1996","unstructured":"Hatva E, B\u00f6hling T, J\u00e4\u00e4skel\u00e4inen J, Persico MG, Haltia M, Alitalo K. Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol. 1996;148(3):763\u201375.","journal-title":"Am J Pathol"},{"key":"1383_CR25","doi-asserted-by":"crossref","unstructured":"Bahrami A, Lee S, Schaefer IM, et al. TERT promoter mutations and prognosis in solitary fibrous tumor. Mod Pathol. 2016;29(12):1511-1522.","DOI":"10.1038\/modpathol.2016.126"},{"issue":"4","key":"1383_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00401-019-01968-3","volume":"137","author":"R Vogels","year":"2019","unstructured":"Vogels R, Macagno N, Griewank K, et al. Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors\/hemangiopericytomas of the CNS: not (yet) clear. Acta Neuropathol. 2019;137(4):679\u201382.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1383_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.humpath.2014.11.018","volume":"46","author":"K Akaike","year":"2015","unstructured":"Akaike K, Kurisaki-Arakawa A, Hara K, et al. Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. Hum Pathol. 2015;46(3):347\u201356.","journal-title":"Hum Pathol"},{"issue":"5","key":"1383_CR28","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00428-014-1625-3","volume":"465","author":"A Kurisaki-Arakawa","year":"2014","unstructured":"Kurisaki-Arakawa A, Akaike K, Hara K, et al. A case of dedifferentiated solitary fibrous tumor in the pelvis with TP53 mutation. Virchows Arch. 2014;465(5):615\u201321.","journal-title":"Virchows Arch"},{"issue":"12","key":"1383_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122913","volume":"13","author":"J Martin-Broto","year":"2021","unstructured":"Martin-Broto J, Mondaza-Hernandez JL, Moura DS, Hindi N. A comprehensive review on solitary fibrous tumor: new insights for New Horizons. Cancers Basel. 2021;13(12):2913.","journal-title":"Cancers Basel"},{"key":"1383_CR30","volume-title":"WHO Classification of Tumours of Soft Tissue and Bone","author":"C Fletcher","year":"2013","unstructured":"Fletcher C, Bridge JA, Hogendoorn P, Mertens F. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Editorial Board: IARC; 2013.","edition":"4"},{"key":"1383_CR31","volume-title":"WHO Classification of Tumors, Soft Tissue and Bone Tumours","author":"EG Demicco","year":"2020","unstructured":"Demicco EG, Fritchie KJ, Han A. WHO Classification of Tumors, Soft Tissue and Bone Tumours. IARC; 2020."},{"issue":"9","key":"1383_CR32","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1097\/PAS.0b013e3181a6cd33","volume":"33","author":"JM Mosquera","year":"2009","unstructured":"Mosquera JM, Fletcher CDM. Expanding the spectrum of malignant progression in solitary fibrous tumors: a study of 8 cases with a discrete anaplastic component\u2013is this dedifferentiated SFT? Am J Surg Pathol. 2009;33(9):1314\u201321.","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"1383_CR33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.5858\/arpa.2016-0570-RS","volume":"142","author":"NJ Olson","year":"2018","unstructured":"Olson NJ, Linos K. Dedifferentiated solitary fibrous tumor: a concise review. Arch Pathol Lab Med. 2018;142(6):761\u20136.","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"1383_CR34","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1038\/modpathol.2012.83","volume":"25","author":"EG Demicco","year":"2012","unstructured":"Demicco EG, Park MS, Araujo DM, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol. 2012;25(9):1298\u2013306.","journal-title":"Mod Pathol"},{"issue":"9","key":"1383_CR35","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jtho.2018.05.040","volume":"13","author":"JS Reisenauer","year":"2018","unstructured":"Reisenauer JS, Mneimneh W, Jenkins S, et al. Comparison of risk stratification models to predict recurrence and survival in pleuropulmonary solitary fibrous tumor. J Thorac Oncol. 2018;13(9):1349\u201362.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"1383_CR36","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/modpathol.2017.54","volume":"30","author":"EG Demicco","year":"2017","unstructured":"Demicco EG, Wagner MJ, Maki RG, et al. Risk assessment in solitary fibrous tumors: validation and refinement of a risk stratification model. Mod Pathol. 2017;30(10):1433\u201342.","journal-title":"Mod Pathol"},{"issue":"10","key":"1383_CR37","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41416-022-01959-4","volume":"127","author":"T Georgiesh","year":"2022","unstructured":"Georgiesh T, Aggerholm-Pedersen N, Sch\u00f6ffski P, et al. Validation of a novel risk score to predict early and late recurrence in solitary fibrous tumour. Br J Cancer. 2022;127(10):1793\u20138.","journal-title":"Br J Cancer"},{"issue":"8","key":"1383_CR38","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/00000478-198908000-00003","volume":"13","author":"DM England","year":"1989","unstructured":"England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol. 1989;13(8):640\u201358.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1383_CR39","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0003-4975(01)03374-4","volume":"74","author":"M de Perrot","year":"2002","unstructured":"de Perrot M, Fischer S, Br\u00fcndler MA, Sekine Y, Keshavjee S. Solitary fibrous tumors of the pleura. Ann Thorac Surg. 2002;74(1):285\u201393.","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"1383_CR40","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ejcts\/ezs629","volume":"44","author":"LF Tapias","year":"2013","unstructured":"Tapias LF, Mino-Kenudson M, Lee H, et al. Risk factor analysis for the recurrence of resected solitary fibrous tumours of the pleura: a 33-year experience and proposal for a scoring system. Eur J Cardiothorac Surg. 2013;44(1):111\u20137.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"1383_CR41","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12931-017-0693-8","volume":"18","author":"M Diebold","year":"2017","unstructured":"Diebold M, Soltermann A, Hottinger S, et al. Prognostic value of MIB-1 proliferation index in solitary fibrous tumors of the pleura implemented in a new score - a multicenter study. Respir Res. 2017;18(1):210.","journal-title":"Respir Res"},{"issue":"1","key":"1383_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43249-4","volume":"14","author":"R Zhang","year":"2023","unstructured":"Zhang R, Yang Y, Hu C, et al. Comprehensive analysis reveals potential therapeutic targets and an integrated risk stratification model for solitary fibrous tumors. Nat Commun. 2023;14(1):7479.","journal-title":"Nat Commun"},{"issue":"1","key":"1383_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s10143-023-02046-9","volume":"46","author":"SM Kwon","year":"2023","unstructured":"Kwon SM, Na MK, Choi KS, et al. Impact of extent of resection and postoperative radiotherapy on survival outcomes in intracranial solitary fibrous tumors: a systematic review and meta-analysis. Neurosurg Rev. 2023;46(1):138.","journal-title":"Neurosurg Rev"},{"issue":"1","key":"1383_CR44","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3171\/2023.4.JNS23147","volume":"140","author":"Y Wu","year":"2024","unstructured":"Wu Y, Zhao T, Cai Y, et al. Clinical outcomes of solitary fibrous tumors and hemangiopericytomas and risk factors related to recurrence and survival based on the 2021 WHO classification of central nervous system tumors. J Neurosurg. 2024;140(1):69\u201379.","journal-title":"J Neurosurg"},{"issue":"3","key":"1383_CR45","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.soc.2022.03.009","volume":"31","author":"K Kazazian","year":"2022","unstructured":"Kazazian K, Demicco EG, de Perrot M, Strauss D, Swallow CJ. Toward better understanding and management of solitary fibrous tumor. Surg Oncol Clin North Am. 2022;31(3):459\u201383.","journal-title":"Surg Oncol Clin North Am"},{"issue":"2","key":"1383_CR46","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.athoracsur.2012.04.028","volume":"94","author":"B Lahon","year":"2012","unstructured":"Lahon B, Mercier O, Fadel E, et al. Solitary fibrous tumor of the pleura: outcomes of 157 complete resections in a single center. Ann Thorac Surg. 2012;94(2):394\u2013400.","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"1383_CR47","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2045-3329-3-4","volume":"3","author":"GG Baldi","year":"2013","unstructured":"Baldi GG, Stacchiotti S, Mauro V, et al. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. Clin Sarcoma Res. 2013;3(1):4.","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"1383_CR48","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/0284186X.2020.1826574","volume":"60","author":"RL Haas","year":"2021","unstructured":"Haas RL, Walraven I, Lecointe-Artzner E, et al. Management of meningeal solitary fibrous tumors\/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy? Acta Oncol. 2021;60(1):35\u201341.","journal-title":"Acta Oncol"},{"issue":"6","key":"1383_CR49","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3171\/2017.7.JNS171226","volume":"129","author":"BS Kim","year":"2018","unstructured":"Kim BS, Kim Y, Kong DS, et al. Clinical outcomes of intracranial solitary fibrous tumor and hemangiopericytoma: analysis according to the 2016 WHO classification of central nervous system tumors. J Neurosurg. 2018;129(6):1384\u201396.","journal-title":"J Neurosurg"},{"issue":"3\u20134","key":"1383_CR50","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.wneu.2013.11.009","volume":"81","author":"AG Melone","year":"2014","unstructured":"Melone AG, D\u2019Elia A, Santoro F, et al. Intracranial hemangiopericytoma\u2013our experience in 30 years: a series of 43 cases and review of the literature. World Neurosurg. 2014;81(3\u20134):556\u201362.","journal-title":"World Neurosurg"},{"issue":"6","key":"1383_CR51","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/cncr.26411","volume":"118","author":"MJ Rutkowski","year":"2012","unstructured":"Rutkowski MJ, Jian BJ, Bloch O, et al. Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer. 2012;118(6):1628\u201336.","journal-title":"Cancer"},{"issue":"1","key":"1383_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0090-3019(02)00917-5","volume":"59","author":"JH Kim","year":"2003","unstructured":"Kim JH, Jung HW, Kim YS, et al. Meningeal hemangiopericytomas: long-term outcome and biological behavior. Surg Neurol. 2003;59(1):47\u201353. discussion 53-4.","journal-title":"Surg Neurol"},{"issue":"1","key":"1383_CR53","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11060-018-2787-7","volume":"138","author":"CJ Kinslow","year":"2018","unstructured":"Kinslow CJ, Bruce SS, Rae AI, et al. Solitary-fibrous tumor\/hemangiopericytoma of the central nervous system: a population-based study. J Neurooncol. 2018;138(1):173\u201382.","journal-title":"J Neurooncol"},{"issue":"3","key":"1383_CR54","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3171\/2010.6.JNS091660","volume":"114","author":"M Schiariti","year":"2011","unstructured":"Schiariti M, Goetz P, El-Maghraby H, Tailor J, Kitchen N. Hemangiopericytoma: long-term outcome revisited. Clinical article. J Neurosurg. 2011;114(3):747\u201355.","journal-title":"J Neurosurg"},{"issue":"7","key":"1383_CR55","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/cncr.20109","volume":"100","author":"S Soyuer","year":"2004","unstructured":"Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH. Intracranial meningeal hemangiopericytoma: the role of radiotherapy: report of 29 cases and review of the literature. Cancer. 2004;100(7):1491\u20137.","journal-title":"Cancer"},{"issue":"2","key":"1383_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1227\/NEU.0b013e31827b9e68","volume":"72","author":"AJ Ghia","year":"2013","unstructured":"Ghia AJ, Allen PK, Mahajan A, Penas-Prado M, McCutcheon IE, Brown PD. Intracranial hemangiopericytoma and the role of radiation therapy: a population based analysis. Neurosurgery. 2013;72(2):203\u20139.","journal-title":"Neurosurgery"},{"issue":"4","key":"1383_CR57","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1227\/00006123-198910000-00003","volume":"25","author":"BL Guthrie","year":"1989","unstructured":"Guthrie BL, Ebersold MJ, Scheithauer BW, Shaw EG. Meningeal hemangiopericytoma: histopathological features, treatment, and long-term follow-up of 44 cases. Neurosurgery. 1989;25(4):514\u201322.","journal-title":"Neurosurgery"},{"issue":"13","key":"1383_CR58","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1002\/cncr.32911","volume":"126","author":"RL Haas","year":"2020","unstructured":"Haas RL, Walraven I, Lecointe-Artzner E, et al. Extrameningeal solitary fibrous tumors-surgery alone or surgery plus perioperative radiotherapy: a retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. Cancer. 2020;126(13):3002\u201312.","journal-title":"Cancer"},{"issue":"1","key":"1383_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-017-1161-0","volume":"15","author":"N Oike","year":"2017","unstructured":"Oike N, Kawashima H, Ogose A, et al. A malignant solitary fibrous tumour arising from the first lumbar vertebra and mimicking an osteosarcoma: a case report. World J Surg Oncol. 2017;15(1):100.","journal-title":"World J Surg Oncol"},{"key":"1383_CR60","doi-asserted-by":"crossref","unstructured":"Ohno M, Kawaguchi Y, Sugino H et al. Resection and postoperative pazopanib for intraspinal recurrent solitary fibrous tumor: illustrative case. J Neurosurg Case Lessons. 2024;8(5).","DOI":"10.3171\/CASE24217"},{"key":"1383_CR61","doi-asserted-by":"crossref","unstructured":"Paudel A, Chattopadhyay P, Rose B et al. Systemic treatment in soft tissue sarcomas: Are we making a difference? Cancers Basel. 2025;17(5).","DOI":"10.3390\/cancers17050889"},{"key":"1383_CR62","doi-asserted-by":"crossref","unstructured":"Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25(13):1760-1764.","DOI":"10.1200\/JCO.2006.07.3411"},{"issue":"1","key":"1383_CR63","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S1470-2045(18)30676-4","volume":"20","author":"J Martin-Broto","year":"2019","unstructured":"Martin-Broto J, Stacchiotti S, Lopez-Pousa A, et al. Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2019;20(1):134\u201344.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1383_CR64","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1093\/annonc\/mds143","volume":"23","author":"S Stacchiotti","year":"2012","unstructured":"Stacchiotti S, Negri T, Libertini M, et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. 2012;23(12):3171\u20139.","journal-title":"Ann Oncol"},{"key":"1383_CR65","doi-asserted-by":"crossref","unstructured":"Martin-Broto J, Cruz J, Penel N, et al. Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21(3):456-466.","DOI":"10.1016\/S1470-2045(19)30826-5"},{"key":"1383_CR66","doi-asserted-by":"crossref","unstructured":"Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. Neurosurgery. 2008;63(4):720-726; author reply 726-7.","DOI":"10.1227\/01.NEU.0000325494.69836.51"},{"issue":"1","key":"1383_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae154","volume":"6","author":"D Limon","year":"2024","unstructured":"Limon D, Amiel A, Even Haim S, et al. A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumor. Neuro Oncol Adv. 2024;6(1):vdae154.","journal-title":"Neuro Oncol Adv"},{"key":"1383_CR68","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1418547","volume":"14","author":"P Wei","year":"2024","unstructured":"Wei P, Lo C, Gao J, Zhu J, Sun X, Li Z. Systemic metastasis in malignant solitary fibrous tumor of the liver: two case reports and literature review. Front Oncol. 2024;14:1418547.","journal-title":"Front Oncol"},{"issue":"8","key":"1383_CR69","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/JTO.0b013e3181803f08","volume":"3","author":"T De Pas","year":"2008","unstructured":"De Pas T, Toffalorio F, Colombo P, et al. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura. J Thorac Oncol. 2008;3(8):938\u201341.","journal-title":"J Thorac Oncol"},{"issue":"17","key":"1383_CR70","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1016\/j.ejca.2014.09.004","volume":"50","author":"S Stacchiotti","year":"2014","unstructured":"Stacchiotti S, Tortoreto M, Baldi GG, et al. Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. Eur J Cancer. 2014;50(17):3021\u20138.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1383_CR71","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13569-015-0022-2","volume":"5","author":"M Maruzzo","year":"2015","unstructured":"Maruzzo M, Martin-Liberal J, Messiou C, et al. Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience. Clin Sarcoma Res. 2015;5(1):5.","journal-title":"Clin Sarcoma Res"},{"key":"1383_CR72","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ejca.2018.10.024","volume":"106","author":"S Stacchiotti","year":"2019","unstructured":"Stacchiotti S, Simeone N, Lo Vullo S, et al. Activity of axitinib in progressive advanced solitary fibrous tumour: results from an exploratory, investigator-driven phase 2 clinical study. Eur J Cancer. 2019;106:225\u201333.","journal-title":"Eur J Cancer"},{"issue":"113391","key":"1383_CR73","doi-asserted-by":"publisher","first-page":"113391","DOI":"10.1016\/j.ejca.2023.113391","volume":"195","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti S, Baldi GG, Frezza AM, et al. Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study. Eur J Cancer. 2023;195(113391):113391.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1383_CR74","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10637-009-9249-1","volume":"28","author":"J Domont","year":"2010","unstructured":"Domont J, Massard C, Lassau N, Armand JP, Le Cesne A, Soria JC. Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma \/solitary fibrous tumour. Invest New Drugs. 2010;28(2):199\u2013202.","journal-title":"Invest New Drugs"},{"issue":"6","key":"1383_CR75","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s10637-013-0023-z","volume":"31","author":"T Valentin","year":"2013","unstructured":"Valentin T, Fournier C, Penel N, et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF\/GETO). Invest New Drugs. 2013;31(6):1626\u20137.","journal-title":"Invest New Drugs"},{"issue":"3","key":"1383_CR76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.trsl.2007.12.007","volume":"151","author":"K Mulamalla","year":"2008","unstructured":"Mulamalla K, Truskinovsky AM, Dudek AZ. Rare case of hemangiopericytoma responds to sunitinib. Transl Res. 2008;151(3):129\u201333.","journal-title":"Transl Res"},{"issue":"19","key":"1383_CR77","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1200\/JCO.2008.20.9890","volume":"27","author":"S George","year":"2009","unstructured":"George S, Merriam P, Maki RG, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27(19):3154\u201360.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1383_CR78","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ejca.2013.03.017","volume":"49","author":"S Stacchiotti","year":"2013","unstructured":"Stacchiotti S, Libertini M, Negri T, et al. Response to chemotherapy of solitary fibrous tumour: a retrospective study. Eur J Cancer. 2013;49(10):2376\u201383.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1383_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/2045-3329-3-7","volume":"3","author":"MS Park","year":"2013","unstructured":"Park MS, Ravi V, Conley A, et al. The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis. Clin Sarcoma Res. 2013;3(1):7.","journal-title":"Clin Sarcoma Res"},{"issue":"8","key":"1383_CR80","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1097\/PAS.0b013e31825748f0","volume":"36","author":"P Collini","year":"2012","unstructured":"Collini P, Negri T, Barisella M, et al. High-grade sarcomatous overgrowth in solitary fibrous tumors: a clinicopathologic study of 10 cases. Am J Surg Pathol. 2012;36(8):1202\u201315.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1383_CR81","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-2407-13-109","volume":"13","author":"A Levard","year":"2013","unstructured":"Levard A, Derbel O, M\u00e9eus P, et al. Outcome of patients with advanced solitary fibrous tumors: the Centre L\u00e9on B\u00e9rard experience. BMC Cancer. 2013;13(1):109.","journal-title":"BMC Cancer"},{"key":"1383_CR82","doi-asserted-by":"crossref","unstructured":"Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015;17(1):116-121","DOI":"10.1093\/neuonc\/nou148"},{"issue":"2","key":"1383_CR83","doi-asserted-by":"publisher","first-page":"e001561","DOI":"10.1136\/jitc-2020-001561","volume":"8","author":"J Martin-Broto","year":"2020","unstructured":"Martin-Broto J, Hindi N, Grignani G, et al. Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib\/II trial. J Immunother Cancer. 2020;8(2):e001561.","journal-title":"J Immunother Cancer"},{"key":"1383_CR84","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ffski P, Timmermans I, Hompes D, et al. Clinical presentation, natural history, and therapeutic approach in patients with solitary fibrous tumor: A retrospective analysis. Sarcoma. 2020;2020:1385978.","DOI":"10.1155\/2020\/1385978"},{"issue":"16suppl","key":"1383_CR85","doi-asserted-by":"publisher","first-page":"11571","DOI":"10.1200\/JCO.2023.41.16_suppl.11571","volume":"41","author":"S Stacchiotti","year":"2023","unstructured":"Stacchiotti S, Grignani G, Vincenzi B, et al. Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): results from a phase II randomised clinical study (STRADA). J Clin Oncol. 2023;41(16suppl):11571\u201311571.","journal-title":"J Clin Oncol"},{"issue":"21","key":"1383_CR86","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1002\/cncr.26098","volume":"117","author":"MS Park","year":"2011","unstructured":"Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117(21):4939\u201347.","journal-title":"Cancer"},{"issue":"1","key":"1383_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-019-0049-6","volume":"4","author":"ATJ Lee","year":"2019","unstructured":"Lee ATJ, Jones RL, Huang PH. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 2019;4(1):16.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1383_CR88","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245\u201355.","journal-title":"Int J Cancer"},{"issue":"11","key":"1383_CR89","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s11864-022-00990-0","volume":"23","author":"JY Blay","year":"2022","unstructured":"Blay JY, Duffaud F, George S, Maki RG, Penel N. Regorafenib for the treatment of sarcoma. Curr Treat Options Oncol. 2022;23(11):1477\u2013502.","journal-title":"Curr Treat Options Oncol"},{"key":"1383_CR90","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/978-3-642-01222-8_3","volume":"184","author":"RJ Kelly","year":"2010","unstructured":"Kelly RJ, Rixe O. Axitinib (AG-013736). Recent Results Cancer Res. 2010;184:33\u201344.","journal-title":"Recent Results Cancer Res"},{"key":"1383_CR91","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/978-3-642-01222-8_6","volume":"184","author":"DYC Heng","year":"2010","unstructured":"Heng DYC, Kollmannsberger C, Sunitinib. Recent Results Cancer Res. 2010;184:71\u201382.","journal-title":"Recent Results Cancer Res"},{"issue":"17","key":"1383_CR92","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.3390\/cancers14174186","volume":"14","author":"S Hidalgo-R\u00edos","year":"2022","unstructured":"Hidalgo-R\u00edos S, Carrillo-Garc\u00eda J, Moura DS, et al. Peripheral inflammatory indexes neutrophil\/lymphocyte ratio (NLR) and red cell distribution width (RDW) as prognostic biomarkers in advanced solitary fibrous tumour (SFT) treated with pazopanib. Cancers Basel. 2022;14(17):4186.","journal-title":"Cancers Basel"},{"key":"1383_CR93","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221116155","volume":"14","author":"A Napolitano","year":"2022","unstructured":"Napolitano A, Moura DS, Hindi N, et al. Expression of p53 as a biomarker of pazopanib efficacy in solitary fibrous tumours: translational analysis of a phase II trial. Ther Adv Med Oncol. 2022;14:17588359221116155.","journal-title":"Ther Adv Med Oncol"},{"issue":"16suppl","key":"1383_CR94","doi-asserted-by":"publisher","first-page":"11540","DOI":"10.1200\/JCO.2025.43.16_suppl.11540","volume":"43","author":"DS Moura","year":"2025","unstructured":"Moura DS, Lopez-Marti J, Stacchiotti S, et al. Predictive gene signature for the efficacy of pazopanib in solitary fibrous tumor: A Spanish Group for Research in Sarcoma (GEIS) study. J Clin Oncol. 2025;43(16suppl):11540\u201311540.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1383_CR95","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/annonc\/mdv598","volume":"27","author":"K Koehler","year":"2016","unstructured":"Koehler K, Liebner D, Chen JL. TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol. 2016;27(3):539\u201343.","journal-title":"Ann Oncol"},{"key":"1383_CR96","doi-asserted-by":"crossref","unstructured":"Wong PP, Yagoda A. Chemotherapy of malignant hemangiopericytoma. Cancer. 1978;41(4):1256-1260.","DOI":"10.1002\/1097-0142(197804)41:4<1256::AID-CNCR2820410406>3.0.CO;2-V"},{"key":"1383_CR97","doi-asserted-by":"crossref","unstructured":"Beadle GF, Hillcoat BL. Treatment of advanced malignant hemangiopericytoma with combination adriamycin and DTIC: a report of four cases. J Surg Oncol. 1983;22(3):167-170.","DOI":"10.1002\/jso.2930220306"},{"issue":"11","key":"1383_CR98","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1470-2045(11)70230-3","volume":"12","author":"P Sch\u00f6ffski","year":"2011","unstructured":"Sch\u00f6ffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045\u201352.","journal-title":"Lancet Oncol"},{"key":"1383_CR99","doi-asserted-by":"crossref","unstructured":"Constantinidou A, Jones RL, Olmos D, et al. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012;51(4):550-554.","DOI":"10.3109\/0284186X.2011.626450"},{"issue":"1","key":"1383_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1697-8","volume":"15","author":"J Khalifa","year":"2015","unstructured":"Khalifa J, Ouali M, Chaltiel L, et al. Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. BMC Cancer. 2015;15(1):700.","journal-title":"BMC Cancer"},{"issue":"6","key":"1383_CR101","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.ejca.2015.01.006","volume":"51","author":"A Le Cesne","year":"2015","unstructured":"Le Cesne A, Ray-Coquard I, Duffaud F, et al. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Eur J Cancer. 2015;51(6):742\u201350.","journal-title":"Eur J Cancer"},{"issue":"2","key":"1383_CR102","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/jjco\/hyw175","volume":"47","author":"A Kawai","year":"2017","unstructured":"Kawai A, Araki N, Naito Y, et al. Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017;47(2):137\u201344.","journal-title":"Jpn J Clin Oncol"},{"key":"1383_CR103","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejca.2017.02.002","volume":"76","author":"S Stacchiotti","year":"2017","unstructured":"Stacchiotti S, Saponara M, Frapolli R, et al. Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin\/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. Eur J Cancer. 2017;76:84\u201392.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1383_CR104","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/cncr.32661","volume":"126","author":"H Kobayashi","year":"2020","unstructured":"Kobayashi H, Iwata S, Wakamatsu T, et al. Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study. Cancer. 2020;126(6):1253\u201363.","journal-title":"Cancer"},{"key":"1383_CR105","doi-asserted-by":"crossref","unstructured":"Li ZK, Liu J, Chen C, Yang KY, Deng YT, Jiang Y. Locally advanced malignant solitary fibrous tumour successfully treated with conversion chemotherapy, operation and postoperative radiotherapy: a case report. J Int Med Res. 2021;49(3):300060521996940.","DOI":"10.1177\/0300060521996940"},{"key":"1383_CR106","doi-asserted-by":"crossref","unstructured":"Cote GM, Haddox CL, Choy E, et al. Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS). J Clin Oncol. 2023;41(16_suppl):11507-11507.","DOI":"10.1200\/JCO.2023.41.16_suppl.11507"},{"issue":"4","key":"1383_CR107","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3109\/0284186X.2011.626450","volume":"51","author":"A Constantinidou","year":"2012","unstructured":"Constantinidou A, Jones RL, Olmos D, et al. Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour. Acta Oncol. 2012;51(4):550\u20134.","journal-title":"Acta Oncol"},{"issue":"18","key":"1383_CR108","doi-asserted-by":"publisher","first-page":"5192","DOI":"10.1158\/1078-0432.CCR-13-0776","volume":"19","author":"S Stacchiotti","year":"2013","unstructured":"Stacchiotti S, Tortoreto M, Bozzi F, et al. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-\u00e0-vis temozolomide and antiangiogenics. Clin Cancer Res. 2013;19(18):5192\u2013201.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1383_CR109","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(15)70098-7","volume":"16","author":"A Kawai","year":"2015","unstructured":"Kawai A, Araki N, Sugiura H, et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. Lancet Oncol. 2015;16(4):406\u201316.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1383_CR110","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1158\/1535-7163.MCT-08-0848","volume":"8","author":"C Forni","year":"2009","unstructured":"Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther. 2009;8(2):449\u201357.","journal-title":"Mol Cancer Ther"},{"key":"1383_CR111","doi-asserted-by":"crossref","unstructured":"Fazel M, Dufresne A, Vanacker H, Waissi W, Blay JY, Brahmi M. Immunotherapy for soft tissue sarcomas: anti-PD1\/PDL1 and beyond. Cancers Basel. 2023;15(6).","DOI":"10.3390\/cancers15061643"},{"issue":"10","key":"1383_CR112","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","volume":"389","author":"AP Chen","year":"2023","unstructured":"Chen AP, Sharon E, O\u2019Sullivan-Coyne G, et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med. 2023;389(10):911\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1383_CR113","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1159\/000484041","volume":"10","author":"JT Boothe","year":"2017","unstructured":"Boothe JT, Budd GT, Smolkin MB, Ma PC. Durable near-complete response to anti-PD-1 checkpoint immunotherapy in a refractory malignant solitary fibrous tumor of the pleura. Case Rep Oncol. 2017;10(3):998\u20131005.","journal-title":"Case Rep Oncol"},{"issue":"1","key":"1383_CR114","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","volume":"4","author":"M Toulmonde","year":"2018","unstructured":"Toulmonde M, Penel N, Adam J, et al. Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial. JAMA Oncol. 2018;4(1):93\u20137.","journal-title":"JAMA Oncol"},{"issue":"8","key":"1383_CR115","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S1470-2045(23)00282-6","volume":"24","author":"JY Le Blay","year":"2023","unstructured":"Blay JY, Chevret S, Le Cesne A, et al. Pembrolizumab in patients with rare and ultra-rare sarcomas (AcS\u00e9 Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial. Lancet Oncol. 2023;24(8):892\u2013902.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1383_CR116","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1097\/NRL.0000000000000572","volume":"29","author":"L Singer","year":"2024","unstructured":"Singer L, Singer J, Horbinski C, Penas-Prado M, Lukas RV. Immunotherapy for solitary fibrous tumor (hemangiopericytoma): a unique treatment approach for a rare central nervous system tumor. Neurologist. 2024;29(4):250\u20133.","journal-title":"Neurologist"},{"issue":"16suppl","key":"1383_CR117","doi-asserted-by":"publisher","first-page":"11551","DOI":"10.1200\/JCO.2022.40.16_suppl.11551","volume":"40","author":"G Lagos","year":"2022","unstructured":"Lagos G, Groisberg R, Elliott A, et al. Using pan-sarcoma multiomic analysis for identifying sarcoma subtypes with immunogenic potential. J Clin Oncol. 2022;40(16suppl):11551\u201311551.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1383_CR118","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/1750743X.2025.2485670","volume":"17","author":"T Assi","year":"2025","unstructured":"Assi T, Moussa T, Le Cesne A. Exploring the role of immune checkpoint inhibitors in solitary fibrous tumors. Immunotherapy. 2025;17(5):305\u20137.","journal-title":"Immunotherapy"},{"key":"1383_CR119","doi-asserted-by":"crossref","unstructured":"Zgura A, Chipuc S, Bacalbasa N, Haineala B, Rodica A, Sebastian V. Evaluating tumour mutational burden as a key biomarker in personalized cancer immunotherapy: a pan-cancer systematic review. Cancers Basel. 2025;17(3).","DOI":"10.3390\/cancers17030480"},{"issue":"6","key":"1383_CR120","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.athoracsur.2020.12.004","volume":"112","author":"LF Tapias","year":"2021","unstructured":"Tapias LF, Mino-Kenudson M, Choy E, et al. Programmed death ligand 1 and immune cell infiltrates in solitary fibrous tumors of the pleura. Ann Thorac Surg. 2021;112(6):1862\u20139.","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"1383_CR121","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/bjc.2014.437","volume":"111","author":"M Tazzari","year":"2014","unstructured":"Tazzari M, Negri T, Rini F, et al. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. Br J Cancer. 2014;111(7):1350\u201362.","journal-title":"Br J Cancer"},{"issue":"12","key":"1383_CR122","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.3390\/cancers12123612","volume":"12","author":"M Albertsmeier","year":"2020","unstructured":"Albertsmeier M, Altendorf-Hofmann A, Lindner LH, et al. Cancer testis antigens and immunotherapy: Expression of PRAME is associated with prognosis in soft tissue sarcoma. Cancers Basel. 2020;12(12):3612.","journal-title":"Cancers Basel"},{"issue":"4","key":"1383_CR123","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2018.08.11","volume":"7","author":"SM Smith","year":"2018","unstructured":"Smith SM, Iwenofu OH. NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis. Chin Clin Oncol. 2018;7(4):44.","journal-title":"Chin Clin Oncol"},{"issue":"12","key":"1383_CR124","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1002\/ijc.34453","volume":"152","author":"M Ishihara","year":"2023","unstructured":"Ishihara M, Nishida Y, Kitano S, et al. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. Int J Cancer. 2023;152(12):2554\u201366.","journal-title":"Int J Cancer"},{"key":"1383_CR125","doi-asserted-by":"crossref","unstructured":"Wermke M, Araujo DM, Chatterjee M et al. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat Med. Published online April 2025.","DOI":"10.1038\/s41591-025-03650-6"},{"issue":"6","key":"1383_CR126","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1038\/modpathol.2012.31","volume":"25","author":"JP Lai","year":"2012","unstructured":"Lai JP, Robbins PF, Raffeld M, et al. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. Mod Pathol. 2012;25(6):854\u20138.","journal-title":"Mod Pathol"},{"issue":"5","key":"1383_CR127","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/s41379-020-00687-5","volume":"34","author":"WL Wang","year":"2021","unstructured":"Wang WL, Gokgoz N, Samman B, Andrulis IL, Wunder JS, Demicco EG. RNA expression profiling reveals PRAME, a potential immunotherapy target, is frequently expressed in solitary fibrous tumors. Mod Pathol. 2021;34(5):951\u201360.","journal-title":"Mod Pathol"},{"issue":"2","key":"1383_CR128","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00428-023-03606-6","volume":"483","author":"C Cammareri","year":"2023","unstructured":"Cammareri C, Beltzung F, Michal M, et al. PRAME immunohistochemistry in soft tissue tumors and mimics: a study of 350 cases highlighting its imperfect specificity but potentially useful diagnostic applications. Virchows Arch. 2023;483(2):145\u201356.","journal-title":"Virchows Arch"},{"issue":"11","key":"1383_CR129","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","volume":"46","author":"M Kaczorowski","year":"2022","unstructured":"Kaczorowski M, Ch\u0142opek M, Kruczak A, Ry\u015b J, Lasota J, Miettinen M. PRAME expression in cancer. A systematic immunohistochemical study of >5800 epithelial and nonepithelial tumors. Am J Surg Pathol. 2022;46(11):1467\u201376.","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1383_CR130","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"1383_CR131","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","volume":"19","author":"SP Van D\u2019Angelo","year":"2018","unstructured":"D\u2019Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416\u201326.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1383_CR132","doi-asserted-by":"publisher","first-page":"R321","DOI":"10.1530\/ERC-13-0231","volume":"20","author":"C Livingstone","year":"2013","unstructured":"Livingstone C. IGF2 and cancer. Endocr Relat Cancer. 2013;20(6):R321\u201339.","journal-title":"Endocr Relat Cancer"},{"issue":"38","key":"1383_CR133","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1038\/onc.2017.116","volume":"36","author":"C Unger","year":"2017","unstructured":"Unger C, Kramer N, Unterleuthner D, et al. Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms. Oncogene. 2017;36(38):5341\u201355.","journal-title":"Oncogene"},{"issue":"4","key":"1383_CR134","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1158\/1078-0432.CCR-10-2621","volume":"17","author":"R Quek","year":"2011","unstructured":"Quek R, Wang Q, Morgan JA, et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011;17(4):871\u20139.","journal-title":"Clin Cancer Res"},{"key":"1383_CR135","doi-asserted-by":"crossref","unstructured":"Stergiopoulos GM, Siontis BL, Ahmed SK, Thangaiah JJ, Houdek MT, Ho TP, Okuno SH, Robinson SI. Case Report: Should IGF-1R targeted therapy be revisited in Ewing sarcoma? a report of long-term complete response and review of the literature. Front Oncol. 2025;15:1667628.","DOI":"10.3389\/fonc.2025.1667628"},{"issue":"7","key":"1383_CR136","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3390\/cancers12071768","volume":"12","author":"HM Amin","year":"2020","unstructured":"Amin HM, Morani AC, Daw NC, et al. IGF-1R\/mTOR targeted therapy for Ewing sarcoma: A meta-analysis of five IGF-1R-related trials matched to proteomic and radiologic predictive biomarkers. Cancers Basel. 2020;12(7):1768.","journal-title":"Cancers Basel"},{"issue":"12","key":"1383_CR137","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.3390\/cancers15123127","volume":"15","author":"Y Li","year":"2023","unstructured":"Li Y, Nguyen JT, Ammanamanchi M, et al. Reduction of tumor growth with RNA-targeting treatment of the NAB2-STAT6 fusion transcript in solitary fibrous tumor models. Cancers Basel. 2023;15(12):3127.","journal-title":"Cancers Basel"},{"issue":"1","key":"1383_CR138","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0169-5002(98)00096-8","volume":"23","author":"YL Chang","year":"1999","unstructured":"Chang YL, Lee YC, Wu CT. Thoracic solitary fibrous tumor: clinical and pathological diversity. Lung Cancer. 1999;23(1):53\u201360.","journal-title":"Lung Cancer"},{"issue":"8","key":"1383_CR139","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00018-022-04454-4","volume":"79","author":"JL Mondaza-Hernandez","year":"2022","unstructured":"Mondaza-Hernandez JL, Moura DS, Lopez-Alvarez M, et al. ISG15 as a prognostic biomarker in solitary fibrous tumour. Cell Mol Life Sci. 2022;79(8):434.","journal-title":"Cell Mol Life Sci"},{"issue":"22","key":"1383_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225602","volume":"14","author":"B Ghanim","year":"2022","unstructured":"Ghanim B, Baier D, Pirker C, et al. Trabectedin is active against two novel, patient-derived solitary fibrous pleural tumor cell lines and synergizes with ponatinib. Cancers. 2022;14(22):5602.","journal-title":"Cancers"},{"issue":"6","key":"1383_CR141","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1002\/cncr.28506","volume":"120","author":"Y Yamada","year":"2014","unstructured":"Yamada Y, Kohashi K, Fushimi F, et al. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors. Cancer. 2014;120(6):864\u201376.","journal-title":"Cancer"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-026-01383-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-026-01383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T09:05:32Z","timestamp":1779095132000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-026-01383-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":141,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1007\/s11864-026-01383-3","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"7 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"26"}}